68Ga-FAP-2286 PET显像在多种癌症中的诊断价值:单中心前瞻性研究与18F-FDG及68Ga-FAPI-46的比较
单中心前瞻性研究纳入64例15种癌症患者行68Ga-FAP-2286 PET/CT,其中63例与18F-FDG配对比较、19例与68Ga-FAPI-46配对比较。68Ga-FAP-2286在原发灶、淋巴结及远处转移的SUVmax均显著高于18F-FDG,病灶检出率更优;与68Ga-FAPI-46的肿瘤摄取和检出率相似。
要点
- 68Ga-FAP-2286在原发瘤、淋巴结转移和远处转移的摄取均显著高于18F-FDG。
- 68Ga-FAP-2286对淋巴结及骨和内脏转移的检出率优于18F-FDG。
- 在19例亚组中,68Ga-FAP-2286与68Ga-FAPI-46的肿瘤摄取和病灶检出率相似。
核心结论
- 68Ga-FAP-2286是用于安全诊断、分期和再分期的有前景的FAP抑制剂衍生物。
- 对于18F-FDG摄取低至中度的癌症类型(包括胃癌、胰腺癌和肝癌),68Ga-FAP-2286可能成为优于18F-FDG的替代选择。
- 68Ga-FAP-2286与68Ga-FAPI-46取得了相当的临床结果。
研究设计与样本
- 单中心前瞻性研究,64例15种癌症患者因初始评估或复发检测接受68Ga-FAP-2286 PET/CT。
- 63例患者接受配对的68Ga-FAP-2286与18F-FDG PET/CT,19例患者接受配对的68Ga-FAP-2286与68Ga-FAPI-46 PET/CT。
- 病灶摄取以SUVmax和肿瘤-本底比量化,采用Wilcoxon配对符号秩检验比较SUVmax,McNemar检验比较病灶检出率。
主要发现
- 原发肿瘤中68Ga-FAP-2286的SUVmax中位数为11.1,18F-FDG为6.9(P < 0.001)。
- 淋巴结转移中68Ga-FAP-2286的SUVmax中位数为10.6,18F-FDG为6.2(P < 0.001)。
- 远处转移中68Ga-FAP-2286摄取显著高于18F-FDG,图像对比度和病灶检出率改善。
- 全部46个原发肿瘤(46/46)经68Ga-FAP-2286 PET/CT清晰显示,其中9个病灶经18F-FDG PET/CT未能显示。
- 淋巴结检出率68Ga-FAP-2286为98%(105/107),18F-FDG为85%(91/107),P = 0.001。
关键数值与推荐
- 原发肿瘤SUVmax中位数:68Ga-FAP-2286 11.1 vs 18F-FDG 6.9,P < 0.001。
- 淋巴结转移SUVmax中位数:68Ga-FAP-2286 10.6 vs 18F-FDG 6.2,P < 0.001。
- 淋巴结检出率:68Ga-FAP-2286 98%(105/107)vs 18F-FDG 85%(91/107),P = 0.001。
- 骨和内脏转移检出率:68Ga-FAP-2286 95%(162/171)vs 18F-FDG 67%(114/171),P < 0.001。
- 在19例亚组中,68Ga-FAP-2286与68Ga-FAPI-46的肿瘤摄取和病灶检出率相似。
临床怎么用
- 作者认为68Ga-FAP-2286是用于安全癌症诊断、分期和再分期的有前景的FAP抑制剂衍生物。
- 作者认为对于18F-FDG摄取低至中度的癌症类型(包括胃癌、胰腺癌和肝癌),68Ga-FAP-2286可能成为优于18F-FDG的替代选择。
- 作者报告68Ga-FAP-2286与68Ga-FAPI-46取得了相当的临床结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET imaging that targets fibroblast activation protein (FAP) on the surface of cancer-associated fibroblasts has yielded promising tumor diagnostic results. FAP-2286 contains cyclic peptides as FAP-binding motifs to optimize tumor retention compared with the small-molecule FAP inhibitor (FAPI) series (FAPI-04/46). The aim of this study was to evaluate the diagnostic accuracy of 68Ga-FAP-2286 to detect primary and metastatic lesions in patients with various types of cancer, compared with 18F-FDG and 68Ga-FAP-2286. Methods: Sixty-four patients with 15 types of cancer underwent 68Ga-FAP-2286 PET/CT for initial assessment or detection of recurrence. For comparison, 63 patients underwent paired 68Ga-FAP-2286 and 18F-FDG PET/CT and 19 patients underwent paired 68Ga-FAP-2286 and 68Ga-FAPI-46 PET/CT. Lesion uptake was quantified as SUVmax and tumor-to-background ratio. The Wilcoxon matched-pairs signed-rank test was used to compare SUVmax between PET modalities, and the McNemar test was used to compare lesion detectability. Results: Uptake of 68Ga-FAP-2286 was significantly higher than that of 18F-FDG in primary tumors (median SUVmax, 11.1 vs. 6.9; P < 0.001), lymph node metastases (median SUVmax, 10.6 vs. 6.2; P < 0.001), and distant metastases, resulting in improved image contrast and lesion detectability. All primary tumors (46/46) were clearly visualized by 68Ga-FAP-2286 PET/CT, whereas 9 of the 46 lesions could not be visualized by 18F-FDG PET/CT. The lesion detection rate of 68Ga-FAP-2286 PET/CT was superior to that of 18F-FDG PET/CT for involved lymph nodes (98% [105/107] vs. 85% [91/107], P = 0.001) and bone and visceral metastases (95% [162/171] vs. 67% [114/171], P < 0.001). 68Ga-FAP-2286 yielded tumor uptake and lesion detection rates similar to those of 68Ga-FAPI-46 in a subcohort of 19 patients. Conclusion: 68Ga-FAP-2286 is a promising FAP-inhibitor derivative for safe cancer diagnosis, staging, and restaging. It may be a better alternative to 18F-FDG for the cancer types that exhibit low-to-moderate uptake of 18F-FDG, which include gastric, pancreatic, and hepatic cancers. In addition, 68Ga-FAP-2286 and 68Ga-FAPI-46 yielded comparable clinical results.
引用
- Pang Y, Zhao L, Meng T, et al. PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using 68Ga-FAP-2286: Comparison with 18F-FDG and 68Ga-FAPI-46 in a Single-Center, Prospective Study. J Nucl Med. 2022. PMID: 36215571. doi:10.2967/jnumed.122.264544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。